NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

RESEARCH & DEVELOPMENT

Recruiting Studies
October, 2024

To find out more about the current studies for you to be involved in or for more information, email us:
bsmhft.researchanddevelopment@nhs.net

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

For the following studies, we need your support to help us recruit eligible participants.

All we need from you is:

- **Identify potentially eligible service users on your caseload** *(support from research team available)*
- **Inform the potential participant about the study.**
- **If interested, ask the potential participant for their consent to contact from the research team.**
- **Share the Rio or NHS Number of interested service users with the research team.**

VISION-QUEST

Birmingham and Solihull Mental Health NHS Foundation Trust

Long Title: VISION-QUEST: A questionnaire study of visual hallucinations

The aim of this study is to develop a new questionnaire to understand more about the way in which people make sense of their visual hallucinations, and the impact it has on their lives. To develop better treatments for people with visions.

Participants will be required to complete an assessment pack on a range of measures that takes approximately 30-45 minutes. These can be completed with support from research staff (in person or virtually over the phone or video call) or on their own, online.

Participants will receive a £10 voucher for each questionnaire pack completed (£20 maximum).

Eligibility Criteria

- Aged 16-65 years, any gender
- Willing and able to give informed consent for study participation.
- Diagnosed with non-affective psychosis.
- Currently experiencing VH (within the last month)
- Currently attending NHS adult secondary or tertiary mental health services

To receive more information or discuss a potentially suitable patient please contact:

Stephanie Fortier: *(stephanie.fortier@nhs.net) OR*
Leah McCauley-Kan *(leah.mccauley-kan@nhs.net)*

PEGASUS

Birmingham and Solihull Mental Health NHS Foundation Trust

Long Title: Understanding experiences of living with and seeking support for cardiovascular health for people with a diagnosis of severe mental illness

The main outcome of this research will be the development of a peer-supported group clinic intervention that is ready to be tested in a feasibility study

Participants will be invited to take part in 'Evidence Based Co-Design workshops' that focus on health awareness to develop improved physical health care for marginalised communities.

Participants will receive a £40 voucher as an appreciation of their time.

Eligibility Criteria

- People accessing mental health services
- Also open to staff *(peer workers & physical and mental healthcare clinicians)*

To receive more information or discuss a potentially suitable patient please contact:

Leah McCauley-Kan: *(leah.mccauley-kan@nhs.net)*
OR ***Indy Athwal*** *(inderpreet.athwal1@nhs.net)*

COPICS

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

Long Title: Experience Based Co-design of Psychosis Centered Integrated Care Services for Ethnically Diverse People with Multimorbidity

The aim of this study is to understand how people from diverse ethnic groups experience and cope with multiple conditions including psychosis, whilst managing adverse social and environmental circumstances. to inform co-production of a range of clinical and training resources to support greater integration of care and services.

Participants will be asked to take photographs, videos or drawings that reflect their thoughts and experiences. Participants will be also required to attend three separate workshops. Participants can bring a friend or family member to all workshops if they wish too.

Participants will receive a £20 voucher at the end of each workshop as a thank you for taking part (£60 in total + travel expenses).

Eligibility Criteria

- Have a diagnosis of Psychosis and **at least two** of the following conditions: diabetes, cardio-respiratory, kidney and liver disease (or be an informal carer for someone with these diagnoses)
- Are from one of three ethnic groups: White British, South Asian, Black African and Black Caribbean.
- Aged over 18.
- Willing and able to provide informed consent
- ***Also open to staff with 6 months experience working with patients with psychosis.***

To receive more information or discuss a potentially suitable patient please contact:

Indy Athwal *(inderpreet.athwal1@nhs.net)*

ADEPP

Birmingham and Solihull Mental Health NHS Foundation Trust

Long Title: Antidepressant for the prevention of DEPression following first episode Psychosis trial

The aim of this study is to establish the effectiveness and cost-effectiveness of an antidepressant medication (sertraline) for the prevention of a depressive episode following first episode psychosis (FEP).

Participants will be required to complete a pack of questionnaires and interviews at certain time points (8 visits in total), have a blood sample taken & take a medication (either sertraline or placebo with no active ingredient) every day for the next 6 months.

Participants will receive £40 as compensation after completing the first visit, and then £20 after the visits at 1, 6, and 12 months (£100 in total) + travel expenses.

Eligibility Criteria

- Aged 18-65
- Diagnosis of First Episode Psychosis (FEP) and started treatment in the last 12 months
- Currently prescribed antipsychotic medication at a stable dose
- Have capacity to consent

To receive more information or discuss a potentially suitable patient please contact:

Stephanie Fortier: *(stephanie.fortier@nhs.net)*

ENROLL-HD

Birmingham and Solihull Mental Health NHS Foundation Trust

Long title: A Prospective Registry Study in a Global Huntington's Disease Cohort

A CHDI Foundation Project

The aim of this study is to learn more about Huntington's Disease (HD) and to try to develop new treatments for the disease.

Participants must attend an annual, in-person visit at the Barberry centre in Birmingham. The initial visit takes approximately 2.5 hours and requires the donation of a blood sample, providing a medical history and going through a series of assessments. Assessments look at how well participants move, think, remember things, perform daily tasks, and behave – all behaviours which may be affected by HD. Every year participants will be invited to a follow-up visit that takes approximately 1.5 hours, involves the same series of assessments that were completed at the initial visit and the option to give a blood sample.

Participants are eligible for a payment to defer the cost of travel.

Eligibility Criteria

- Carrier of the HD CAG repeat expansion but not showing any symptoms
- Carrier of HD CAG repeat expansion and are showing symptoms.
- Have been tested for the CAG repeat expansion but you received a negative result.
- A member of a HD family (spouse/partner).
- Have not been tested to see whether have the CAG repeat expansion but may be at risk of HD

To receive more information or discuss a potentially suitable patient please contact:

Ashley Jones: *(ashley.jones7@nhs.net) OR*
Elsa Benn: *(e.benn@nhs.net)*

SNAPPER

Birmingham and Solihull Mental Health NHS Foundation Trust

Long title: A stratified randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER

The aim of the study is to evaluate the clinical and cost-effectiveness of stimulant (Lisdexamfetamine) compared with non-stimulant (Atomoxetine) medication for adults with Attention-Deficit/Hyperactivity Disorder (ADHD) and a history of either psychosis or bipolar disorder.

Participants will be randomised to receive either a stimulant or non-stimulant medication; and must complete questionnaires about mental health & ADHD plus interviews with the study team (5 times) for 12 months by the ADHD service and research team.

Participants will receive £25 after each questionnaire time point: baseline, 6 months & 12 months (£75 in total).

Eligibility Criteria

- Diagnosis of ADHD, psychosis (schizophrenia spectrum disorders) OR Bipolar disorder
- Stable and on suitable mood stabilisers or antipsychotics
- Males and females aged 18 years and over
- Not currently (or within the last month) on medication for ADHD
- Able to give written informed consent

To receive more information or discuss a potentially suitable patient please contact:

***Paras Joshee**: (p.joshee@nhs.net) OR **Stephanie Fortier:** (stephanie.fortier@nhs.net)*

ASCEnD
Aripiprazole Sertraline Combination Effectiveness

ASCEND

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

Long Title: Aripiprazole/sertraline combination: clinical and cost-effectiveness in comparison with quetiapine for the treatment of bipolar depression. An open label randomised controlled trial.

The aim of this study is to determine the clinical and cost effectiveness of aripiprazole/sertraline combination in the treatment of depressive episodes in people with bipolar disorder.

The purpose of the ASCEND study is to compare a combination of sertraline and aripiprazole to quetiapine as a treatment to bipolar & depression. Therefore, participants will be randomised to receive either a combination of sertraline and aripiprazole OR quetiapine. Participants will also be required to complete questionnaires & weekly questionnaires at home throughout the study (support may be provided from the research team and/or friends & family).

Participants will receive a £50 gift voucher as compensation.

Eligibility Criteria

- Aged 18+
- Have capacity to provide consent
- Have a confirmed diagnosis of a major depressive episode within bipolar disorder
- Have a current QIDS-SR greater than 10.

To receive more information or discuss a potentially suitable patient please contact:

Stephanie Fortier: *(stephanie.fortier@nhs.net)*

PURVIEW STUDY

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

PURVIEW

Long Title :A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON'S DISEASE

The aim of this study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with HD

PURVIEW is a long term, open-label study to evaluate the safety and tolerability of SAGE-718, a novel oral medicine that aims to treat the cognitive dysfunction associated with premanifest or early manifest Huntington's Disease. Participants will receive the active investigational medicine for up to 365 days and will be required to complete a series of clinical and cognitive assessments on a periodic basis.

Food and travel expenses are reimbursed

Eligibility Criteria

- Aged 25 – 65 at time of screening
- Confirmed diagnosis of Huntington's Disease with CAG expansion 40
- Be capable of providing informed consent in the opinion of the investigator
- A study partner aged 18 is recommended

To receive more information or discuss a potentially suitable patient please contact:

Susan Musa *(s.musa2@nhs.net) OR* ***Prof. Hugh Rickards***

STARS

Birmingham and Solihull Mental Health NHS Foundation Trust

Long Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES

The aim of this study is to evaluate the safety and effectiveness of an investigational drug inhaler in the treatment of epilepsy.

The STARS Study is testing an inhaler containing an investigational drug that has been designed to quickly stop a prolonged seizure once it has begun. Throughout the course of the study, the participants will be required to maintain regular e-diaries detailing seizure activity, as well as attend periodic telephone and onsite appointments to conduct clinical assessments.

Food and travel expenses are reimbursed

Eligibility Criteria

- 12 years of age or older
- Have focal or generalised epilepsy, or a combination of the two
- Have experienced at least 2 prolonged seizures within the past 3 months
- Have an adult who can act as a study partner to assist you throughout the study

To receive more information or discuss a potentially suitable patient please contact:

Susan Musa *(s.musa2@nhs.net),* ***Anika Miah*** *(anika.miah1@nhs.net) OR* ***Dr Manny Bagary***

PSYCHEDELIC CLINICAL TRIAL FOR TRD

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

Long Title: An Open-Label, Phase 2a, Single Dose Study to Evaluate the Safety Tolerability and Pharmacodynamics of BPL-003 in Patients with Treatment Resistant Depression (TRD)

The aim of the study is to evaluate the safety, tolerability, efficacy, PK and PD of a single intranasal dose of BPL-003 combined with psychotherapy in patients with TRD, when administered as a monotherapy

We are looking for people with a diagnosis of Treatment Resistant Depression (TRD) i.e depression that has not responded to two or more medications, aged 18 to 75, to take part in a trial using 5-MeO-DMT. 5-MeO-DMT is a 'psychedelic' drug, used both recreationally and in ceremonial settings due to its psychoactive properties.Taking part will involve 2 sessions of 1 night's residence on our wards in London (you may stay 2 additional nights) and 11 outpatient visits (several may be video calls)

Participants will receive a full medical check-up and a payment between £2,250 and £2,890 plus travel expenses reimbursed.

Eligibility Criteria

- Aged 18 to 75
- have Treatment Resistant Depression (TRD) and either
- not be taking any antidepressants, or
- be taking other antidepressants and be willing to discontinue them - we will assist you in doing this

To receive more information or discuss a potentially suitable patient please contact:

Stephanie Fortier: *(stephanie.fortier@nhs.net)*

I-CARE

Birmingham and Solihull Mental Health NHS Foundation Trust

Long Title: InCreAsing Retention of healthcare staff from Ethnic minority groups (I-CARE) – Work Package 3 - Consented Longitudinal Cohort Study

The aim of this study is to improve our understanding of the personal and work-related factors that are related to healthcare workers' intentions to change or leave their jobs, and sickness absence. In particular, focusing on minoritized groups (focusing on ethnicity and migration status), and to explore potential reasons for this.

Participants will be asked to complete the I-CARE questionnaire, which will take around 25 minutes. Questions will ask basic information about participants, their ethnicity, plus any thoughts or actions around changing or leaving their healthcare role, and also their attitudes and experiences at work.

Participants will receive Amazon gift vouchers as compensation.

Eligibility Criteria

- Age 16 years or above
- Lives and works in the United Kingdom
- Healthcare worker or ancillary worker in a healthcare setting
- Willing and able to give informed consent

To receive more information or discuss a potentially suitable patient please contact:

Analisa Smythe: a.smythe@nhs.net

I-MARK-HD

NHS
Birmingham and Solihull Mental Health
NHS Foundation Trust

Long Title: Longitudinal Adaptive Study of Molecular Pathology and Neuronal Networks in Huntington's Disease Gene Expansion Carriers (HDGEC) and Healthy Controls using Positron Emission Tomography (PET) and Multi-modal Magnetic Resonance Imaging (MRI)

The aim of this study of this study is to identify clinical and imaging biomarkers of HD progression for use in clinical trials of disease-modifying therapies.

Participation in the study will include clinical observations for up to 2 years & will take place at Baseline, 1 Year and 2 Year time points. The primary goal is to derive candidate pharmacodynamic biomarkers across the different stages of HD that could be used as markers of disease progression and be further developed to measure the efficacy of novel pharmacological treatments for HD.

Participant is reimbursed for travel, lodging accommodation, a meal and the participant receives a stipend for taking part in the research activities.

Eligibility Criteria

- Confirmed Htt CAG repeat length 40
- Age 21 to 75 at the time of screening
- Capable of giving informed consent
- Adequate visual (Snellen chart) and auditory (Rinne and Weber tests) acuity to complete the psychological testing
- Must comply with highly effective contraceptive measures
- Absence of clinically significant diseases
- Willing to travel to KCH/KCL

To receive more information or discuss a potentially suitable patient please contact:

Elsa Benn: e.benn@nhs.net